News | January 04, 2026
Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Applications include detailed scientific rationale and supporting clinical evidence
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
